A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors

Status

Terminated

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02880371

Enrollment

Registered

2016-08-26

Start date

2016-09-01

Completion date

2019-10-24

Last updated

2022-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

Keywords

Advanced Solid Tumors, Pembrolizumab, ARRY-382, CSF-1R, CSF1R, cfms

Brief summary

This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in adult patients with selected advanced solid tumors (Part A/Phase 1b); and to estimate the efficacy of the combination in three separate cohorts: 1) patients with advanced solid tumors that have progressed on prior PD-1/PD-L1inhibitors, 2) patients with platinum-resistant ovarian cancer and 3) patients with pancreatic ductal adenocarcinoma (Phase 2).

Detailed description

ARRY-382 is an inhibitor of CSF1R (colony-stimulating factor-1 receptor). Each phase of the study consists of a 28-day screening period; 21-day treatment cycles with the combination of ARRY-382 and pembrolizumab until disease progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, or death (or other discontinuation criteria are met), and a 30-day safety follow-up period. Patients in all cohorts/phases will be monitored for overall survival (OS) until 1 year after the date of the last patient's first visit.

Interventions

DRUGARRY-382

ARRAY-382 will be taken by mouth once daily at a fixed dose.

DRUGPembrolizumab

Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria All Study Parts: * Diagnosis of cancer that has been histologically or cytologically confirmed * Eastern Cooperative Oncology Group Performance Status of 0 or 1 Part A (1 of the following): * Ovarian cancer, triple-negative breast cancer, head and neck squamous cell cancer, bladder cancer, metastatic colorectal cancer, pancreatic ductal adenocarcinoma, or gastric cancer that is measurable or evaluable, nonmeasurable as defined by RECIST v1.1 and meets 1 of the following criteria: * is refractory to standard of care * no standard therapy available * patient refuses standard therapy * Advanced, unresectable, or metastatic melanoma with or without prior treatment and measurable or evaluable, nonmeasurable disease as defined by RECIST v1.1 * Advanced/metastatic PD-L1-positive NSCLC (defined as a tumor proportion score \[TPS\] ≥ 50%) with measurable or evaluable, non-measurable disease as defined by RECIST v1.1 (1 of the following): * 1\) No prior systemic chemotherapy if tumor does not have EGFR or ALK genomic aberrations * 2\) Disease progression on or after platinum-containing chemotherapy; * 3\) If tumor has EGFR or ALK genomic aberrations, disease progression on an FDA-approved therapy for EGFR or ALK genomic tumor aberrations Phase 2 (1 of the following): * Advanced/metastatic solid tumor with PD as defined by RECIST 1.1 or irRC on an anti-PD-1- or anti-PD-L1-containing regimen as their most recent prior therapy * Advanced/metastatic epithelial ovarian cancer, peritoneal cancer or tubal cancer with measurable disease as defined by RECIST 1.1, that had progressed within 6 months of completing ≥ 4 cycles of platinum-based therapy * Advanced/metastatic PDA that is locally advanced, unresectable or metastatic with measurable disease as defined by RECIST v1.1 in patients who have received at least one prior line of systemic therapy for their disease Key

Exclusion criteria

1. Prior treatment as follows: * Part A: an immune CPI (e.g., PD-1, PD-L1, or cytotoxic T-lymphocyte antigen 4 \[CTLA-4\] inhibitor). NOTE: For patients with melanoma, prior treatment with ipilimumab is allowed if it was administered as adjuvant therapy and treatment was completed at least 3 months prior to enrollment. * Phase 2: * A CSF-1R inhibitor or CSF-1 (or MCSF) inhibitor. * prOVCA and PDA patients only: an immune CPI (e.g., PD-1, PD-L1, or CTLA-4 inhibitor) 2. Symptomatic brain metastasis at screening 3. Active autoimmune disease, documented history of autoimmune syndrome or disease, or a chronic medical condition that requires chronic steroid therapy or immunosuppressive medication 4. History of pneumonitis or interstitial lung disease 5. Severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient an inappropriate candidate for the study 6. Ocular melanoma

Design outcomes

Primary

Measure	Time frame	Description
Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)	Cycle 1 (up to 21 days)	DLT: adverse event (AE) or abnormal laboratory value not clearly attributable to an extraneous cause, such as disease progression, intercurrent illness, or concomitant medications occurring during 21 days of Cycle 1, met 1 of the criteria A) nonhematologic AEs: recurring grade 2 pneumonitis, grade 3 events (irAE, QTcF prolongation, rash; other grade 3/4 except alopecia, nausea, diarrhea, vomiting, tumor flare, pseudoprogression, endocrinopathy); B) hematology AEs/laboratory abnormalities: grade 4 events except lymphopenia, neutropenia, electrolyte imbalances or abnormalities, grade 3 thrombocytopenia, febrile neutropenia, grade 4 AST/ALT elevation, grade 3 AST/ALT elevation lasting \>7 days, associated with bilirubin levels\>=2\ULN or international normalized ratio \>1.5, grade 3 bilirubin elevation \>=3, CK elevation \>=grade 3 lasting, increase in creatinine \>=1.5\baseline value, dose delay (dose interruption for \>14 days) or other (inability to receive at least 67% of ARRY-382 doses).
Phase 2 Cohorts: Objective Response Rate (ORR)	From day of first dose to 30 days after last dose (maximum up to 13.5 months)	ORR was defined as the percentage of participants who achieved a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator review of radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<) 10 millimeter (mm). PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-progressive disease (PD). The analysis was based on confirmed responses for which CR or PR must be confirmed by repeat disease assessment studies performed no less than 4 weeks after the criteria for response were first met to qualify as CR or PR, respectively.

Secondary

Measure	Time frame	Description
Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)	From day of first dose until disease progression or death due to any cause or till last tumor assessment date (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	PFS was defined as the time from the date of first dose of study drug to the earliest date of disease progression per RECIST v1.1, or death due to any cause, whichever occurs first. If a participant did not have a PFS event at the time of the analysis cut-off or at the start of any new anticancer therapy, PFS was censored at the date of last adequate tumor assessment. PD = at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of \>= 5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions.
Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)	From day of first dose till death due to any cause or date of last contact (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	OS was defined as the time from the start of treatment to the date of death due to any cause. If a death was not observed by the date of the analysis cut-off, OS was censored at the date of last contact. OS was estimated using the Kaplan-Meier method.
Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)	From day of first dose till up to end of study treatment (for Phase 1b: maximum up to 33.7 months, for Phase 2: maximum up to 12.5 months)	irRR was defined as the percentage of participants who achieved immune-related best overall response (irBOR) of immune-related CR (irCR) or immune-related PR (irPR), as determined by the investigator per immune related response criteria (irRC). irBOR was the best response using irRC recorded from the start of study treatment until the end of treatment. irCR was the disappearance of all target lesions, irPR was a decrease in tumor burden by 50% or greater by a consecutive assessment at least 4 weeks after first documentation.
Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)	From the start of treatment to the time of first documented progression, or death (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	irPFS was defined as the time from the start of treatment to the time of first documented progression per irRC, or death due to any cause. irRC criteria for progression for 1) Measurable new lesions: incorporated into the tumor burden (eg, added to the index lesions); do not define progression unless the total measurable tumor burden increases by the required amount (25%); 2) New non-measurable lesions: not considered progression if the total measurable tumor burden is stable or shrinking. For the analysis of irPFS, Kaplan-Meier method was used.
Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Baseline, Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment discontinuation (before 13.5 months)	Tumor markers were measured for tumor type from serum samples obtained from participants in Phase 2. Mean change from baseline was reported in this outcome measure.
Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	Abnormalities: Albumin (hypoalbuminemia),Alkaline phosphatase (ALP increased), Alanine aminotransferase (ALT increased), Aspartate aminotransferase (AST increased),Total bilirubin (TBL increased), Creatinine (increased), Corrected calcium (hypocalcemia/hypercalcemia), Creatine kinase (CK increased), Glucose (hypoglycemia/hyperglycemia), Amylase (increased), Lipase (increased) ,Phosphate (hypophosphatemia), Magnesium (hypomagnesemia/hypermagnesemia), Potassium (hypokalemia/hyperkalemia), Sodium (hyponatremia/hypernatremia). Participants with all grades and grade 3/4 abnormalities were reported. Test abnormalities were graded by CTCAE v4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening.
Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	Hematology abnormalities: Hemoglobin (anemia/hemoglobin increased), Platelets (count decreased), Leukocytes (count decreased/increased), Neutrophils (count decreased), Lymphocytes (count increased/decreased). Coagulation abnormalities: International Normalized Ratio (INR increased), Partial thromboplastin time(PTT)/Activated partial thromboplastin Time (aPTT, time prolonged). Abnormalities were graded by CTCAE grade 4.03 as Grade 1= mild; Grade 2 = moderate; Grade 3/Grade 4 = severe/life-threatening. Participants with all grades and grade 3/4 abnormalities were reported.
Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	Liver function parameters/abnormalities: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT): \>3\* upper limit of normal (ULN), \>5\ULN, \>8\ULN, \>10\ULN, \>20\ULN; Bilirubin \>1.5\ULN, \>2\ULN; Alkaline phosphatase (ALP) \>2\ULN, \>3\ULN.
Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Baseline, 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	Thyroid panel laboratory parameters/abnormalities: thyrotropin, free triiodothyronine (T3), free thyroxine (T4). Shift in thyroid panel severity from baseline grade low, normal, high and missing to the post baseline grades as low, normal, high and missing is reported in this outcome measure.
Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding	First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	Urinalysis laboratory parameters/abnormalities: Decimal logarithm of reciprocal of hydrogen ion activity (pH), specific gravity, protein, glucose, ketones, nitrite, blood, leukocyte esterase, microscopy (if urine tested positive for blood or protein). Clinical significance was judged by investigator.
Phase 1b, Part A: Objective Response Rate (ORR)	From day of first dose to 30 days after last dose (maximum up to 34.7 months)	ORR was defined as the percentage of participants who achieved a BOR of CR or PR as determined by investigator review of radiographic disease assessments per RECIST v1.1. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD. The analysis was based on confirmed responses for which CR or PR must be confirmed by repeat disease assessment studies performed no less than 4 weeks after the criteria for response were first met to qualify as CR or PR, respectively.
Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hour(hr) (±5 min), 2 hours(hrs) (±10 min), 4 hrs (±20 min) and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2	The lower limit of quantitation (LLOQ) for analyte ARRY-382 was 5.00 nanogram per milliliter (ng/mL).
Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2	Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00469099 was reported in this outcome measure. The LLOQ for analyte AR00469099 was 1.00 ng/mL.
Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2	Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00469100 was reported in this outcome measure. The LLOQ for analyte AR00469100 was 1.00 ng/mL.
Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2	Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00470870 was reported in this outcome measure. The LLOQ for analyte AR00470870 was 1.00 ng/mL.
Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	0 to 24 hrs after administration of ARRY-382 on Day 1 of Cycle 2	AUCtau was defined as area under the plasma concentration-time curve over the dosing interval, where dosing interval was 24 hours.
Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Pre dose of ARRY-382 (120 minutes prior to administration), 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2	Cmax was obtained from plasma concentration time curve. Cmax at single dose was reported at Cycle1 Day 1 and Cmax at steady state was reported at Cycle 2 Day 1.
Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Pre dose of ARRY-382 (120 minutes prior to administration) on Day 1 of Cycle 2	Measured concentration at the pre-dose at steady-state.
Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Pre dose of ARRY-382 (120 minutes prior to administration), 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2	Tmax was obtained from plasma concentration time curve. Tmax at single dose was reported at Cycle 1 Day 1 and Tmax at steady state was reported at Cycle 2 Day 1.
Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Pre dose of ARRY-382 (120 minutes prior to administration),1 hrs (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2	Different MR reported for single dose calculated at Cycle 1 Day 1 were as follows: 1) MRAUClast = ratio of AUClast values of the metabolite compared to parent, corrected for molecular weight, where AUClast was area under the plasma concentration-time curve from zero to the last measurable time point; 2) MRCmax = ratio of Cmax values of the metabolite compared to parent, corrected for molecular weight. Different MR reported for steady state calculated at Cycle 2 Day 1 were as follows: 1) MRAUCtau,ss = ratio of AUCtau,ss values of the metabolite compared to parent, corrected for molecular weight, where AUCtau was area under the plasma concentration-time curve over a dosing interval at steady-state; 2) MRCmax,ss = Ratio of Cmax,ss values of the metabolite compared to parent, corrected for molecular weight.
Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Pre dose of ARRY-382 (120 minutes prior to administration),1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2	Accumulation ratio was calculated and reported for Cmax as RCmax and for AUC as RAUC. RCmax = Cmax at steady-state on Day 1 of Cycle 2 divided by Cmax on Day 1 of Cycle 1. RAUC = AUC from zero to 8 hours after drug administration at steady-state on Day 1 of Cycle 2 divided by AUC from zero to 8 hours after drug administration on Day 1 of Cycle 1.
Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body temperature and weight. Low SBP: less than or equal to (\<=)90 millimeter of mercury (mmHg) with decrease from baseline of \>=20 mmHg. High SBP: \>=160 mmHg with increase from baseline of \>=20 mmHg. Low DBP: \<=50 mmHg with decrease from baseline of \>=15 mmHg. High DBP: \>=100 mmHg with increase from baseline of \>=15 mmHg. Low heart rate: \<=50 beats/min with decrease from baseline of \>=15 beats/min. High heart rate: \>=120 beats/min with increase from baseline of \>=15 beats/min. Low temperature: \<=36 degree Celsius (C). High temperature: \>=37.5 degree C. Low Weight: decrease from baseline \>=20%. High weight: increase from baseline \>=10%.
Phase 1b, Part A and Phase 2 Cohorts: Duration of Response (DOR)	From date of first documented CR or PR up to disease progression or death (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)	DOR was defined as the time from the date of the first documented response (CR or PR) to the earliest date of disease progression, or death due to any cause after achieving a response. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \< 10 mm. PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. PD = at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of \>= 5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions. DOR was estimated using the Kaplan-Meier method.

Countries

United States

Participant flow

Recruitment details

This study had 2 phases: Phase 1B and 2. Originally, Phase 1b of the study had Part A and B. Part A was dose escalation in participants with selected advanced solid tumors. Part B was expansion in melanoma participants. Part C was a part of Phase 2, in participants with non-small cell lung cancer (NSCLC).

Pre-assignment details

There was an amendment in protocol, which removed originally designed Part B and C, due to low enrolment. Post-implementation of this amendment 2, Part B and C were replaced with 3 cohorts in Phase 2. Study then had Part A (Phase 1b), and 3 cohorts in Phase 2. Cohorts of Phase 2 were as follows: 1) PD-1/PD-L1 inhibitor-refractory cohort, 2) pancreatic ductal adenocarcinoma cohort and 3) platinum-resistant ovarian cancer cohort.

Participants by arm

Arm	Count
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab Participants with selected advanced solid tumors received ARRY-382 capsules at a dose of 200 mg orally, QD in combination with pembrolizumab at a dose of 2 mg/kg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	6
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab Participants with selected advanced solid tumors received ARRY-382 capsules at a dose of 300 mg orally, QD in combination with pembrolizumab at a dose of 2 mg/kg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	6
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab Participants with selected advanced solid tumors received ARRY-382 capsules at a dose of 400 mg orally, QD in combination with pembrolizumab at a dose of 2 mg/kg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	7
Phase 1b, Part B: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab Participants with melanoma received ARRY-382 capsules at a dose of 300 mg orally, QD in combination with pembrolizumab at a dose of 2 mg/kg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	1
Phase 2, Part C: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab Participants with NSCLC received ARRY-382 capsules at a dose of 300 mg orally, QD in combination with pembrolizumab at a dose of 2 mg/kg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort Participants who progressed on a PD-1/ PD-L1 inhibitor-containing regimen as their most recent prior line of therapy and were new to prior CSF-1R or CSF-1 inhibitors were included in this reporting arm. Participants received ARRY-382 capsules at a dose of 300 mg orally, QD in combination with pembrolizumab at a dose of 200 mg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	19
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort Participants with PDA who had at least 1 prior line of therapy and were new to prior CPI therapy and to prior CSF-1R or CSF-1 inhibitors were included in this reporting arm. Participants received ARRY-382 capsules at a dose of 300 mg orally, QD in combination with pembrolizumab at a dose of 200 mg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	27
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort Participants with prOVCA who had at least 1 prior line of therapy and were new to prior CPI therapy and to prior CSF-1R or CSF-1 inhibitors were included in this reporting arm. Participants received ARRY-382 capsules at a dose of 300 mg orally, QD in combination with pembrolizumab at a dose of 200 mg IV Q3W in each 21-day treatment cycle until disease progression, participant refusal, lost to follow-up, unacceptable toxicity, or the study termination by the sponsor and a 30-day safety follow-up period.	11
Total	79

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007
Phase 1b	Death	4	6	5	1	0	0	0	0
Phase 1b	Enrolled but not Treated	0	1	0	0	0	0	0	0
Phase 1b	Lost to Follow-up	1	0	0	0	0	0	0	0
Phase 1b	Participants terminated by Sponsor	1	0	0	0	0	0	0	0
Phase 1b	Withdrawal by Subject	0	0	1	0	0	0	0	0
Phase 2	Death	0	0	0	0	1	10	20	5
Phase 2	End of Study page not completed by error	0	0	0	0	0	1	0	0
Phase 2	Enrolled but not Treated	0	0	0	0	0	1	1	0
Phase 2	Lost to Follow-up	0	0	0	0	0	0	3	0
Phase 2	Other	0	0	0	0	0	1	2	1
Phase 2	Participants terminated by Sponsor	0	0	0	0	1	6	1	5
Phase 2	Withdrawal by Subject	0	0	0	0	0	1	1	0

Baseline characteristics

Characteristic	Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part B: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2, Part C: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Total
Age, Continuous	63.7 years STANDARD_DEVIATION 12.4	52.2 years STANDARD_DEVIATION 16	54.7 years STANDARD_DEVIATION 12.9	68.0 years	47.0 years STANDARD_DEVIATION 0	63.1 years STANDARD_DEVIATION 12	65.0 years STANDARD_DEVIATION 9.6	59.3 years STANDARD_DEVIATION 13.1	61.6 years STANDARD_DEVIATION 12.2
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	2 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	5 Participants	6 Participants	7 Participants	1 Participants	2 Participants	18 Participants	23 Participants	10 Participants	72 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	3 Participants	1 Participants	5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	3 Participants	2 Participants	0 Participants	5 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	1 Participants	5 Participants
Race (NIH/OMB) White	5 Participants	6 Participants	7 Participants	1 Participants	2 Participants	15 Participants	23 Participants	9 Participants	68 Participants
Sex: Female, Male Female	2 Participants	3 Participants	4 Participants	0 Participants	0 Participants	12 Participants	12 Participants	11 Participants	44 Participants
Sex: Female, Male Male	4 Participants	3 Participants	3 Participants	1 Participants	2 Participants	7 Participants	15 Participants	0 Participants	35 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk
deaths Total, all-cause mortality	4 / 6	6 / 6	5 / 7	1 / 1	1 / 2	10 / 19	20 / 27	5 / 11
other Total, other adverse events	6 / 6	6 / 6	6 / 7	1 / 1	2 / 2	19 / 19	26 / 27	10 / 11
serious Total, serious adverse events	3 / 6	1 / 6	3 / 7	1 / 1	1 / 2	8 / 19	15 / 27	5 / 11

Outcome results

Primary

Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)

DLT: adverse event (AE) or abnormal laboratory value not clearly attributable to an extraneous cause, such as disease progression, intercurrent illness, or concomitant medications occurring during 21 days of Cycle 1, met 1 of the criteria A) nonhematologic AEs: recurring grade 2 pneumonitis, grade 3 events (irAE, QTcF prolongation, rash; other grade 3/4 except alopecia, nausea, diarrhea, vomiting, tumor flare, pseudoprogression, endocrinopathy); B) hematology AEs/laboratory abnormalities: grade 4 events except lymphopenia, neutropenia, electrolyte imbalances or abnormalities, grade 3 thrombocytopenia, febrile neutropenia, grade 4 AST/ALT elevation, grade 3 AST/ALT elevation lasting \>7 days, associated with bilirubin levels\>=2\*ULN or international normalized ratio \>1.5, grade 3 bilirubin elevation \>=3, CK elevation \>=grade 3 lasting, increase in creatinine \>=1.5\*baseline value, dose delay (dose interruption for \>14 days) or other (inability to receive at least 67% of ARRY-382 doses).

Time frame: Cycle 1 (up to 21 days)

Population: Dose-determining set (DDS) included all participants in Phase 1b who received at least 67% of the planned cumulative dose of ARRY-382 during Cycle 1 or discontinued the treatment because of DLT.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)	2 Participants

Primary

Phase 2 Cohorts: Objective Response Rate (ORR)

ORR was defined as the percentage of participants who achieved a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator review of radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<) 10 millimeter (mm). PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-progressive disease (PD). The analysis was based on confirmed responses for which CR or PR must be confirmed by repeat disease assessment studies performed no less than 4 weeks after the criteria for response were first met to qualify as CR or PR, respectively.

Time frame: From day of first dose to 30 days after last dose (maximum up to 13.5 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Value (NUMBER)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 Cohorts: Objective Response Rate (ORR)	0.0 percentage of participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 Cohorts: Objective Response Rate (ORR)	3.7 percentage of participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 Cohorts: Objective Response Rate (ORR)	0.0 percentage of participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Accumulation ratio was calculated and reported for Cmax as RCmax and for AUC as RAUC. RCmax = Cmax at steady-state on Day 1 of Cycle 2 divided by Cmax on Day 1 of Cycle 1. RAUC = AUC from zero to 8 hours after drug administration at steady-state on Day 1 of Cycle 2 divided by AUC from zero to 8 hours after drug administration on Day 1 of Cycle 1.

Time frame: Pre dose of ARRY-382 (120 minutes prior to administration),1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2

Population: PK set included all participants who had received any active study intervention (ARRY-382), with at least one postdose blood draw to determineplasma concentration of ARRY-382 and its metabolites (AR00469099, AR00469100 and AR00470870). Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure and Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RCmax	3.03 ratio	Geometric Coefficient of Variation 53.4
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RAUC	3.47 ratio	Geometric Coefficient of Variation 94.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RCmax	2.72 ratio	Geometric Coefficient of Variation 54.5
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RAUC	3.49 ratio	Geometric Coefficient of Variation 51.7
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RAUC	4.03 ratio	Geometric Coefficient of Variation 93
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RAUC	3.03 ratio	Geometric Coefficient of Variation 47.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RCmax	2.53 ratio	Geometric Coefficient of Variation 48.2
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RCmax	2.67 ratio	Geometric Coefficient of Variation 46.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RAUC	1.97 ratio	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RCmax	2.51 ratio	Geometric Coefficient of Variation 95.7
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RCmax	2.60 ratio	Geometric Coefficient of Variation 157
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RCmax	2.54 ratio	Geometric Coefficient of Variation 52
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RAUC	4.48 ratio	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RAUC	4.36 ratio	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RAUC	1.92 ratio	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RCmax	3.59 ratio	Geometric Coefficient of Variation 95.3
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RCmax	2.50 ratio	Geometric Coefficient of Variation 65.1
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RAUC	3.96 ratio	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RAUC	2.73 ratio	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RAUC	3.52 ratio	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RCmax	2.02 ratio	Geometric Coefficient of Variation 20.1
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RCmax	2.28 ratio	Geometric Coefficient of Variation 54.2
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RAUC	4.28 ratio	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RCmax	2.47 ratio	Geometric Coefficient of Variation 38.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RAUC	2.64 ratio	Geometric Coefficient of Variation 36.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RAUC	2.67 ratio	Geometric Coefficient of Variation 36.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RCmax	2.39 ratio	Geometric Coefficient of Variation 48.6
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RAUC	4.01 ratio	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RCmax	3.19 ratio	Geometric Coefficient of Variation 36.7
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RCmax	2.44 ratio	Geometric Coefficient of Variation 41.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RCmax	2.52 ratio	Geometric Coefficient of Variation 39.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RAUC	4.67 ratio	—
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RAUC	3.30 ratio	Geometric Coefficient of Variation 61.9
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RCmax	2.07 ratio	Geometric Coefficient of Variation 53.6
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RCmax	2.08 ratio	Geometric Coefficient of Variation 49
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RAUC	3.41 ratio	Geometric Coefficient of Variation 23.6
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RAUC	4.95 ratio	Geometric Coefficient of Variation 41.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RCmax	3.56 ratio	Geometric Coefficient of Variation 48.4
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RAUC	3.84 ratio	Geometric Coefficient of Variation 13.5
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RCmax	2.03 ratio	Geometric Coefficient of Variation 38.7
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RCmax	1.76 ratio	Geometric Coefficient of Variation 29.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RAUC	2.03 ratio	Geometric Coefficient of Variation 23.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RCmax	1.93 ratio	Geometric Coefficient of Variation 37.4
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 RAUC	2.07 ratio	Geometric Coefficient of Variation 23.8
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RAUC	1.87 ratio	Geometric Coefficient of Variation 16.7
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382 RCmax	1.62 ratio	Geometric Coefficient of Variation 24.7
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 RCmax	1.77 ratio	Geometric Coefficient of Variation 31
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 RAUC	1.93 ratio	Geometric Coefficient of Variation 23

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

AUCtau was defined as area under the plasma concentration-time curve over the dosing interval, where dosing interval was 24 hours.

Time frame: 0 to 24 hrs after administration of ARRY-382 on Day 1 of Cycle 2

Population: PK set included all participants who had received any active study intervention (ARRY-382), with at least one post dose blood draw to determine plasma concentration of ARRY-382 and its metabolites (AR00469099, AR00469100 and AR00470870). Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure and Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	2170 hour*nanogram per milliliter	Geometric Coefficient of Variation 85.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	3180 hour*nanogram per milliliter	Geometric Coefficient of Variation 59
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	4150 hour*nanogram per milliliter	Geometric Coefficient of Variation 63.5
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	22800 hour*nanogram per milliliter	Geometric Coefficient of Variation 44.2
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	30600 hour*nanogram per milliliter	Geometric Coefficient of Variation 26.6
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	3860 hour*nanogram per milliliter	Geometric Coefficient of Variation 33.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	9810 hour*nanogram per milliliter	Geometric Coefficient of Variation 29.3
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	4530 hour*nanogram per milliliter	Geometric Coefficient of Variation 106
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	30800 hour*nanogram per milliliter	Geometric Coefficient of Variation 130
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	5880 hour*nanogram per milliliter	Geometric Coefficient of Variation 78.8
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	6200 hour*nanogram per milliliter	Geometric Coefficient of Variation 45.2
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	3510 hour*nanogram per milliliter	Geometric Coefficient of Variation 142
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	2670 hour*nanogram per milliliter	Geometric Coefficient of Variation 53.4
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	7920 hour*nanogram per milliliter	Geometric Coefficient of Variation 18.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	6850 hour*nanogram per milliliter	Geometric Coefficient of Variation 61.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	32100 hour*nanogram per milliliter	Geometric Coefficient of Variation 65.7
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	5360 hour*nanogram per milliliter	Geometric Coefficient of Variation 62.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	47100 hour*nanogram per milliliter	Geometric Coefficient of Variation 10.2
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	7940 hour*nanogram per milliliter	Geometric Coefficient of Variation 36.9
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	14200 hour*nanogram per milliliter	Geometric Coefficient of Variation 123
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	2840 hour*nanogram per milliliter	Geometric Coefficient of Variation 61.8
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	2480 hour*nanogram per milliliter	Geometric Coefficient of Variation 73.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	8220 hour*nanogram per milliliter	Geometric Coefficient of Variation 20.3
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	20700 hour*nanogram per milliliter	Geometric Coefficient of Variation 70.6

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Measured concentration at the pre-dose at steady-state.

Time frame: Pre dose of ARRY-382 (120 minutes prior to administration) on Day 1 of Cycle 2

Population: PK set included all participants who had received any active study intervention (ARRY-382), with at least one post dose blood draw to determine plasma concentration of ARRY-382 and its metabolites (AR00469099, AR00469100 and AR00470870). Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure and Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	60.1 nanogram per milliliter	Geometric Coefficient of Variation 103
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	136 nanogram per milliliter	Geometric Coefficient of Variation 67.7
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	576 nanogram per milliliter	Geometric Coefficient of Variation 59.5
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	99.1 nanogram per milliliter	Geometric Coefficient of Variation 80.8
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	146 nanogram per milliliter	Geometric Coefficient of Variation 105
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	96.0 nanogram per milliliter	Geometric Coefficient of Variation 43.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	313 nanogram per milliliter	Geometric Coefficient of Variation 41.7
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	667 nanogram per milliliter	Geometric Coefficient of Variation 27.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	161 nanogram per milliliter	Geometric Coefficient of Variation 105
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	627 nanogram per milliliter	Geometric Coefficient of Variation 126
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	83.6 nanogram per milliliter	Geometric Coefficient of Variation 137
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	185 nanogram per milliliter	Geometric Coefficient of Variation 27.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	82.4 nanogram per milliliter	Geometric Coefficient of Variation 57.1
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	878 nanogram per milliliter	Geometric Coefficient of Variation 70.1
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	277 nanogram per milliliter	Geometric Coefficient of Variation 27.1
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	232 nanogram per milliliter	Geometric Coefficient of Variation 58.5
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	1480 nanogram per milliliter	Geometric Coefficient of Variation 17.5
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	557 nanogram per milliliter	Geometric Coefficient of Variation 136
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	193 nanogram per milliliter	Geometric Coefficient of Variation 71.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	302 nanogram per milliliter	Geometric Coefficient of Variation 48.1
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469099	77.1 nanogram per milliliter	Geometric Coefficient of Variation 85.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	ARRY-382	438 nanogram per milliliter	Geometric Coefficient of Variation 86.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00470870	224 nanogram per milliliter	Geometric Coefficient of Variation 34.1
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	AR00469100	57.1 nanogram per milliliter	Geometric Coefficient of Variation 99.2

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Duration of Response (DOR)

DOR was defined as the time from the date of the first documented response (CR or PR) to the earliest date of disease progression, or death due to any cause after achieving a response. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \< 10 mm. PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. PD = at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of \>= 5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions. DOR was estimated using the Kaplan-Meier method.

Time frame: From date of first documented CR or PR up to disease progression or death (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab. This outcome measure was evaluated in participants who achieved an objective response. Overall Number of participants Analyzed =0, signifies participants did not had documented CR or PR for respective reporting arms.

Arm	Measure	Value (MEDIAN)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Duration of Response (DOR)	29.2 months
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Duration of Response (DOR)	3.1 months
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Duration of Response (DOR)	2.4 months

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)

irPFS was defined as the time from the start of treatment to the time of first documented progression per irRC, or death due to any cause. irRC criteria for progression for 1) Measurable new lesions: incorporated into the tumor burden (eg, added to the index lesions); do not define progression unless the total measurable tumor burden increases by the required amount (25%); 2) New non-measurable lesions: not considered progression if the total measurable tumor burden is stable or shrinking. For the analysis of irPFS, Kaplan-Meier method was used.

Time frame: From the start of treatment to the time of first documented progression, or death (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Value (MEDIAN)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)	3.0 months
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)	2.5 months
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)	1.3 months
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)	1.5 months
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)	1.3 months
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)	2.5 months

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Cmax was obtained from plasma concentration time curve. Cmax at single dose was reported at Cycle1 Day 1 and Cmax at steady state was reported at Cycle 2 Day 1.

Time frame: Pre dose of ARRY-382 (120 minutes prior to administration), 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2

Population: PK set included all participants who had received any active study intervention (ARRY-382), with at least one post dose blood draw to determine plasma concentration of ARRY-382 and its metabolites (AR00469099, AR00469100 and AR00470870). Here Number Analyzed signifies number of participants evaluated for given time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	61.2 nanogram per milliliter	Geometric Coefficient of Variation 78.3
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	84.0 nanogram per milliliter	Geometric Coefficient of Variation 102
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	138 nanogram per milliliter	Geometric Coefficient of Variation 81.6
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	212 nanogram per milliliter	Geometric Coefficient of Variation 57.3
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	773 nanogram per milliliter	Geometric Coefficient of Variation 60.2
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	172 nanogram per milliliter	Geometric Coefficient of Variation 51.6
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	1560 nanogram per milliliter	Geometric Coefficient of Variation 41.3
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	70.1 nanogram per milliliter	Geometric Coefficient of Variation 95.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	2260 nanogram per milliliter	Geometric Coefficient of Variation 36.6
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	534 nanogram per milliliter	Geometric Coefficient of Variation 22
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	995 nanogram per milliliter	Geometric Coefficient of Variation 68.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	104 nanogram per milliliter	Geometric Coefficient of Variation 86.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	100 nanogram per milliliter	Geometric Coefficient of Variation 59.8
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	241 nanogram per milliliter	Geometric Coefficient of Variation 103
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	174 nanogram per milliliter	Geometric Coefficient of Variation 92.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	257 nanogram per milliliter	Geometric Coefficient of Variation 36.4
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	219 nanogram per milliliter	Geometric Coefficient of Variation 83.8
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	122 nanogram per milliliter	Geometric Coefficient of Variation 41.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	333 nanogram per milliliter	Geometric Coefficient of Variation 60.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	2560 nanogram per milliliter	Geometric Coefficient of Variation 117
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	1330 nanogram per milliliter	Geometric Coefficient of Variation 39.6
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	328 nanogram per milliliter	Geometric Coefficient of Variation 75.6
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	196 nanogram per milliliter	Geometric Coefficient of Variation 58.5
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	268 nanogram per milliliter	Geometric Coefficient of Variation 141
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	119 nanogram per milliliter	Geometric Coefficient of Variation 50.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	2130 nanogram per milliliter	Geometric Coefficient of Variation 60.4
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	328 nanogram per milliliter	Geometric Coefficient of Variation 44
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	132 nanogram per milliliter	Geometric Coefficient of Variation 70
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	181 nanogram per milliliter	Geometric Coefficient of Variation 56.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	193 nanogram per milliliter	Geometric Coefficient of Variation 60.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	1240 nanogram per milliliter	Geometric Coefficient of Variation 62.1
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	373 nanogram per milliliter	Geometric Coefficient of Variation 60.6
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	147 nanogram per milliliter	Geometric Coefficient of Variation 98.9
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	363 nanogram per milliliter	Geometric Coefficient of Variation 30.9
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	116 nanogram per milliliter	Geometric Coefficient of Variation 98.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	646 nanogram per milliliter	Geometric Coefficient of Variation 111
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	142 nanogram per milliliter	Geometric Coefficient of Variation 97.9
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	2820 nanogram per milliliter	Geometric Coefficient of Variation 15.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	279 nanogram per milliliter	Geometric Coefficient of Variation 54.9
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	1290 nanogram per milliliter	Geometric Coefficient of Variation 75.6
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	486 nanogram per milliliter	Geometric Coefficient of Variation 18.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	231 nanogram per milliliter	Geometric Coefficient of Variation 50.8
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	215 nanogram per milliliter	Geometric Coefficient of Variation 52.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	1260 nanogram per milliliter	Geometric Coefficient of Variation 53.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	95.4 nanogram per milliliter	Geometric Coefficient of Variation 43.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	138 nanogram per milliliter	Geometric Coefficient of Variation 46.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	161 nanogram per milliliter	Geometric Coefficient of Variation 50.8
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	1580 nanogram per milliliter	Geometric Coefficient of Variation 64.8

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Different MR reported for single dose calculated at Cycle 1 Day 1 were as follows: 1) MRAUClast = ratio of AUClast values of the metabolite compared to parent, corrected for molecular weight, where AUClast was area under the plasma concentration-time curve from zero to the last measurable time point; 2) MRCmax = ratio of Cmax values of the metabolite compared to parent, corrected for molecular weight. Different MR reported for steady state calculated at Cycle 2 Day 1 were as follows: 1) MRAUCtau,ss = ratio of AUCtau,ss values of the metabolite compared to parent, corrected for molecular weight, where AUCtau was area under the plasma concentration-time curve over a dosing interval at steady-state; 2) MRCmax,ss = Ratio of Cmax,ss values of the metabolite compared to parent, corrected for molecular weight.

Time frame: Pre dose of ARRY-382 (120 minutes prior to administration),1 hrs (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2

Population: PK set included all participants who had received any active study intervention (ARRY-382), with at least one post dose blood draw to determine plasma concentration of ARRY-382 and its metabolites (AR00469099, AR00469100 and AR00470870). Here Number Analyzed signifies number of participants evaluated for given time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRAUCtau,ss	0.0978 ratio	Geometric Coefficient of Variation 43.8
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRAUClast	0.0817 ratio	Geometric Coefficient of Variation 40.7
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRCmax	0.0811 ratio	Geometric Coefficient of Variation 45
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRCmax,ss	0.0909 ratio	Geometric Coefficient of Variation 41.4
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRCmax	0.0775 ratio	Geometric Coefficient of Variation 119
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRCmax,ss	0.0941 ratio	Geometric Coefficient of Variation 84.4
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRAUClast	0.115 ratio	Geometric Coefficient of Variation 86.8
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRAUClast	0.0946 ratio	Geometric Coefficient of Variation 104
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRCmax	0.106 ratio	Geometric Coefficient of Variation 58.8
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRAUCtau,ss	0.119 ratio	Geometric Coefficient of Variation 80.2
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRAUCtau,ss	0.177 ratio	Geometric Coefficient of Variation 35.6
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRCmax,ss	0.132 ratio	Geometric Coefficient of Variation 20.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRCmax,ss	0.116 ratio	Geometric Coefficient of Variation 29.3
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRCmax,ss	0.201 ratio	Geometric Coefficient of Variation 36.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRAUClast	0.159 ratio	Geometric Coefficient of Variation 42.7
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRAUCtau,ss	0.144 ratio	Geometric Coefficient of Variation 80.3
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRAUClast	0.101 ratio	Geometric Coefficient of Variation 47.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRAUCtau,ss	0.129 ratio	Geometric Coefficient of Variation 27.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRCmax	0.107 ratio	Geometric Coefficient of Variation 35
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRCmax	0.0979 ratio	Geometric Coefficient of Variation 74.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRAUClast	0.101 ratio	Geometric Coefficient of Variation 33.4
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRAUCtau,ss	0.273 ratio	Geometric Coefficient of Variation 43.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRCmax	0.149 ratio	Geometric Coefficient of Variation 26.6
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRCmax,ss	0.103 ratio	Geometric Coefficient of Variation 68.2
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRAUClast	0.0934 ratio	Geometric Coefficient of Variation 31
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRCmax	0.0941 ratio	Geometric Coefficient of Variation 21.8
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRCmax,ss	0.111 ratio	Geometric Coefficient of Variation 42.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRAUCtau,ss	0.186 ratio	Geometric Coefficient of Variation 84.6
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRAUClast	0.127 ratio	Geometric Coefficient of Variation 44.9
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRCmax,ss	0.125 ratio	Geometric Coefficient of Variation 74.8
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRCmax	0.160 ratio	Geometric Coefficient of Variation 79.5
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRAUCtau,ss	0.172 ratio	Geometric Coefficient of Variation 66.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRAUClast	0.151 ratio	Geometric Coefficient of Variation 70.9
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRCmax	0.126 ratio	Geometric Coefficient of Variation 30.4
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRAUCtau,ss	0.117 ratio	Geometric Coefficient of Variation 13.1
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRCmax,ss	0.108 ratio	Geometric Coefficient of Variation 24.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRCmax,ss	0.150 ratio	Geometric Coefficient of Variation 89.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRAUCtau,ss	0.240 ratio	Geometric Coefficient of Variation 69
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRCmax	0.133 ratio	Geometric Coefficient of Variation 78
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRAUCtau,ss	0.182 ratio	Geometric Coefficient of Variation 69.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRCmax,ss	0.150 ratio	Geometric Coefficient of Variation 66.6
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRAUClast	0.101 ratio	Geometric Coefficient of Variation 45.7
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRCmax	0.0929 ratio	Geometric Coefficient of Variation 46.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRAUClast	0.104 ratio	Geometric Coefficient of Variation 39.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRCmax	0.109 ratio	Geometric Coefficient of Variation 47.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRAUCtau,ss	0.0853 ratio	Geometric Coefficient of Variation 13.8
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRCmax,ss	0.0873 ratio	Geometric Coefficient of Variation 19.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRAUClast	0.151 ratio	Geometric Coefficient of Variation 71.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRCmax,ss	0.222 ratio	Geometric Coefficient of Variation 108
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRCmax	0.0923 ratio	Geometric Coefficient of Variation 41.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRCmax	0.107 ratio	Geometric Coefficient of Variation 71.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRAUCtau,ss	0.292 ratio	Geometric Coefficient of Variation 132
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRAUCtau,ss	0.144 ratio	Geometric Coefficient of Variation 41.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRAUCtau,ss	0.117 ratio	Geometric Coefficient of Variation 66.4
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRCmax,ss	0.101 ratio	Geometric Coefficient of Variation 52.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRAUClast	0.108 ratio	Geometric Coefficient of Variation 63.4
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRCmax,ss	0.110 ratio	Geometric Coefficient of Variation 31.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRCmax	0.0974 ratio	Geometric Coefficient of Variation 51.4
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRAUClast	0.106 ratio	Geometric Coefficient of Variation 64
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRAUClast	0.0883 ratio	Geometric Coefficient of Variation 41.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRCmax,ss	0.0991 ratio	Geometric Coefficient of Variation 24
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRCmax,ss	0.140 ratio	Geometric Coefficient of Variation 44.3
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRCmax	0.112 ratio	Geometric Coefficient of Variation 29.8
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRAUClast	0.176 ratio	Geometric Coefficient of Variation 72.4
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099 MRAUCtau,ss	0.134 ratio	Geometric Coefficient of Variation 27.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRCmax,ss	0.263 ratio	Geometric Coefficient of Variation 59.6
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100 MRAUClast	0.108 ratio	Geometric Coefficient of Variation 22.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870 MRAUCtau,ss	0.340 ratio	Geometric Coefficient of Variation 59
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100 MRAUCtau,ss	0.123 ratio	Geometric Coefficient of Variation 40.8
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRCmax	0.0734 ratio	Geometric Coefficient of Variation 38.3
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099 MRAUClast	0.0821 ratio	Geometric Coefficient of Variation 31.3
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870 MRCmax	0.156 ratio	Geometric Coefficient of Variation 71.6

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding

Urinalysis laboratory parameters/abnormalities: Decimal logarithm of reciprocal of hydrogen ion activity (pH), specific gravity, protein, glucose, ketones, nitrite, blood, leukocyte esterase, microscopy (if urine tested positive for blood or protein). Clinical significance was judged by investigator.

Time frame: First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: Safety set included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding	0 Participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests

Liver function parameters/abnormalities: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT): \>3\* upper limit of normal (ULN), \>5\*ULN, \>8\*ULN, \>10\*ULN, \>20\*ULN; Bilirubin \>1.5\*ULN, \>2\*ULN; Alkaline phosphatase (ALP) \>2\*ULN, \>3\*ULN.

Time frame: First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: Safety set included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >5*ULN	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >20*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALP >3ULN and Total Bilirubin >2ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >3ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >8*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >3*ULN	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >10*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >2*ULN	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >20*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >10*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >20*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >2*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >3*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >3*ULN	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST >3ULN and ALP <2ULN and Total Bilirubin >2*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >10ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >8*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >5*ULN	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >5*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >3*ULN	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >10*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >8*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >1.5*ULN	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >5ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >3*ULN	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >5*ULN	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >5ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >20*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >20*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >8*ULN	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >10*ULN	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALP >3ULN and Total Bilirubin >2ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >10*ULN	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >8*ULN	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST >3ULN and ALP <2ULN and Total Bilirubin >2*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >3ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >5*ULN	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >20*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >3*ULN	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >8*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >2*ULN	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >10*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >2*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >3*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >1.5*ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >3*ULN	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >10ULN	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >5*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALP >3ULN and Total Bilirubin >2ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >5ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >10ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >10*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST >3ULN and ALP <2ULN and Total Bilirubin >2*ULN	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >20*ULN	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >2*ULN	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >3*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >3*ULN	4 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >5*ULN	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >5*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >8*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >10*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >20*ULN	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >1.5*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >2*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >3*ULN	4 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >5*ULN	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >8*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >8*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >10*ULN	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >20*ULN	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >3*ULN	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >3ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >3ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST >3ULN and ALP <2ULN and Total Bilirubin >2*ULN	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >10*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >10ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >8*ULN	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >20*ULN	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >8*ULN	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >20*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALP >3ULN and Total Bilirubin >2ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >5ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >10*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >3*ULN	7 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >5*ULN	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >2*ULN	5 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >8*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >1.5*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >10*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >3*ULN	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >2*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >3*ULN	7 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >5*ULN	4 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >5*ULN	4 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >20*ULN	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >3*ULN	4 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >20*ULN	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >3*ULN	9 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >1.5*ULN	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >2*ULN	12 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >3ULN	4 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >2*ULN	4 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >3*ULN	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >20*ULN	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >3*ULN	13 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST >3ULN and ALP <2ULN and Total Bilirubin >2*ULN	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >10*ULN	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >20*ULN	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >5*ULN	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >5ULN	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >8*ULN	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALP >3ULN and Total Bilirubin >2ULN	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >10*ULN	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >8*ULN	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >8*ULN	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >10*ULN	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >5*ULN	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >5*ULN	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >10ULN	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >3*ULN	13 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >3*ULN	5 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >3*ULN	4 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >5*ULN	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >8*ULN	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >10*ULN	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alanine Aminotransferase: >20*ULN	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >2*ULN	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Alkaline Phosphatase: >3*ULN	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >3*ULN	5 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >5*ULN	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >8*ULN	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >10*ULN	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Aspartate Aminotransferase: >20*ULN	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >1.5*ULN	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	Bilirubin: >2*ULN	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >5*ULN	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >8*ULN	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >10*ULN	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST: AT >20*ULN	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >3ULN	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >5ULN	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST and Total Bilirubin >2ULN: AT >10ULN	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALP >3ULN and Total Bilirubin >2ULN	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests	ALT or AST >3ULN and ALP <2ULN and Total Bilirubin >2*ULN	0 Participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities

Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body temperature and weight. Low SBP: less than or equal to (\<=)90 millimeter of mercury (mmHg) with decrease from baseline of \>=20 mmHg. High SBP: \>=160 mmHg with increase from baseline of \>=20 mmHg. Low DBP: \<=50 mmHg with decrease from baseline of \>=15 mmHg. High DBP: \>=100 mmHg with increase from baseline of \>=15 mmHg. Low heart rate: \<=50 beats/min with decrease from baseline of \>=15 beats/min. High heart rate: \>=120 beats/min with increase from baseline of \>=15 beats/min. Low temperature: \<=36 degree Celsius (C). High temperature: \>=37.5 degree C. Low Weight: decrease from baseline \>=20%. High weight: increase from baseline \>=10%.

Time frame: First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: Safety set included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab. Here, Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: High	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: Low	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: High	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: Low	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: High	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: Low	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: Low	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: High	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: High	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: Low	4 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: Low	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: Low	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: High	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: High	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: High	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: Low	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: Low	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: Low	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: High	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: High	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: Low	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: High	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: High	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: Low	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: High	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: Low	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: High	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: Low	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: High	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: Low	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: High	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: Low	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: High	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: Low	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: High	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: Low	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: High	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: Low	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: Low	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: High	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: High	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: Low	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: High	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: Low	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: Low	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: Low	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: High	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: High	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: High	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: Low	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: Low	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: Low	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: High	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Temperature: High	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: Low	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: Low	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Weight: High	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	SBP: High	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	Heart Rate: High	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities	DBP: Low	0 Participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03

Hematology abnormalities: Hemoglobin (anemia/hemoglobin increased), Platelets (count decreased), Leukocytes (count decreased/increased), Neutrophils (count decreased), Lymphocytes (count increased/decreased). Coagulation abnormalities: International Normalized Ratio (INR increased), Partial thromboplastin time(PTT)/Activated partial thromboplastin Time (aPTT, time prolonged). Abnormalities were graded by CTCAE grade 4.03 as Grade 1= mild; Grade 2 = moderate; Grade 3/Grade 4 = severe/life-threatening. Participants with all grades and grade 3/4 abnormalities were reported.

Time frame: First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: Safety set included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: All Grades	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: All Grades	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: Grade 3/4	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: All Grades	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: All Grades	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: All Grades	4 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: All Grades	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: All Grades	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: All Grades	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: All Grades	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: All Grades	5 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: Grade 3/4	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: All Grades	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: All Grades	4 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: All Grades	12 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: Grade 3/4	4 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: All Grades	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: All Grades	11 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: Grade 3/4	5 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: All Grades	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: Grade 3/4	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: All Grades	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: Grade 3/4	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: Grade 3/4	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: All Grades	6 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: Grade 3/4	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: All Grades	9 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: Grade 3/4	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: All Grades	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: Grade 3/4	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: All Grades	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: Grade 3/4	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: All Grades	9 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: All Grades	7 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: All Grades	11 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: Grade 3/4	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: All Grades	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: Grade 3/4	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: All Grades	15 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: All Grades	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: All Grades	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: Grade 3/4	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: All Grades	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: All Grades	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: All Grades	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: All Grades	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Neutrophils (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Prothrombin Intl. Normalized Ratio (INR Units), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hyper: All Grades	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Platelets (10^9/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hypo: All Grades	7 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Activated Partial Thromboplastin Time (sec), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: Grade 3/4	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Hemoglobin (g/L), Hyper: All Grades	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Lymphocytes (10^9/L), Hypo: All Grades	5 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03	Leukocytes (10^9/L), Hypo: All Grades	2 Participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03

Abnormalities: Albumin (hypoalbuminemia),Alkaline phosphatase (ALP increased), Alanine aminotransferase (ALT increased), Aspartate aminotransferase (AST increased),Total bilirubin (TBL increased), Creatinine (increased), Corrected calcium (hypocalcemia/hypercalcemia), Creatine kinase (CK increased), Glucose (hypoglycemia/hyperglycemia), Amylase (increased), Lipase (increased) ,Phosphate (hypophosphatemia), Magnesium (hypomagnesemia/hypermagnesemia), Potassium (hypokalemia/hyperkalemia), Sodium (hyponatremia/hypernatremia). Participants with all grades and grade 3/4 abnormalities were reported. Test abnormalities were graded by CTCAE v4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening.

Time frame: First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: Safety set included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: All Grades	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (g/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: All Grades	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: All Grades	5 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (millimoles per liter [mmol/L]), Hypo: All Grades	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (grams per liter [g/L]), Hypo: All Grades	4 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (umol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: Grade 3/4	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: All Grades	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (micromoles per liter [umol/L]), Hyper: All Grades	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: All Grades	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: All Grades	5 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: All Grades	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: All Grades	5 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: Grade 3/4	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (U/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: All Grades	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: All Grades	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: All Grades	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (units per liter [U/L]), Hyper: All Grades	5 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (units per liter [U/L]), Hyper: All Grades	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: All Grades	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (U/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: All Grades	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: All Grades	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: All Grades	4 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (grams per liter [g/L]), Hypo: All Grades	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: All Grades	6 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: Grade 3/4	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (micromoles per liter [umol/L]), Hyper: All Grades	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (umol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (millimoles per liter [mmol/L]), Hypo: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (g/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: All Grades	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: Grade 3/4	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: All Grades	4 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: All Grades	5 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: Grade 3/4	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: All Grades	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (millimoles per liter [mmol/L]), Hypo: All Grades	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: All Grades	4 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (g/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (units per liter [U/L]), Hyper: All Grades	4 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (U/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (grams per liter [g/L]), Hypo: All Grades	4 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: All Grades	3 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: Grade 3/4	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: All Grades	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: All Grades	6 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: All Grades	5 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (micromoles per liter [umol/L]), Hyper: All Grades	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: All Grades	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: All Grades	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: All Grades	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: All Grades	3 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (umol/L), Hyper: Grade 3/4	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: All Grades	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: All Grades	6 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: All Grades	8 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (grams per liter [g/L]), Hypo: All Grades	5 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (g/L), Hypo: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (units per liter [U/L]), Hyper: All Grades	11 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (U/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: All Grades	8 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: Grade 3/4	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: All Grades	11 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: Grade 3/4	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: All Grades	17 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: Grade 3/4	4 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (micromoles per liter [umol/L]), Hyper: All Grades	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (umol/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (millimoles per liter [mmol/L]), Hypo: All Grades	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: All Grades	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: All Grades	16 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: Grade 3/4	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: All Grades	7 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: Grade 3/4	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: All Grades	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: Grade 3/4	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: All Grades	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: All Grades	7 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: Grade 3/4	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: All Grades	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: Grade 3/4	7 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: All Grades	5 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: All Grades	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: Grade 3/4	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: All Grades	8 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: All Grades	4 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (units per liter [U/L]), Hyper: All Grades	17 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: Grade 3/4	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (g/L), Hypo: Grade 3/4	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: All Grades	23 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: All Grades	6 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: Grade 3/4	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: All Grades	7 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: All Grades	20 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: All Grades	7 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: Grade 3/4	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: All Grades	4 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: Grade 3/4	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (millimoles per liter [mmol/L]), Hypo: All Grades	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: All Grades	12 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: All Grades	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (grams per liter [g/L]), Hypo: All Grades	10 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: All Grades	13 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (umol/L), Hyper: Grade 3/4	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (U/L), Hyper: Grade 3/4	4 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: All Grades	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: Grade 3/4	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: All Grades	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (micromoles per liter [umol/L]), Hyper: All Grades	7 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: All Grades	6 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: All Grades	4 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: All Grades	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: All Grades	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: All Grades	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: Grade 3/4	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: Grade 3/4	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: Grade 3/4	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: All Grades	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: Grade 3/4	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: All Grades	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: Grade 3/4	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatine Kinase (U/L), Hyper: All Grades	7 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: All Grades	5 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hyper: All Grades	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (g/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Lipase (U/L), Hyper: Grade 3/4	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Calcium (millimoles per liter [mmol/L]), Hypo: All Grades	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: All Grades	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (umol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Bilirubin (micromoles per liter [umol/L]), Hyper: All Grades	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: All Grades	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: All Grades	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Aspartate Aminotransferase (U/L), Hyper: All Grades	11 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Magnesium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: Grade 3/4	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Amylase (U/L), Hyper: All Grades	7 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: All Grades	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: Grade 3/4	3 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Albumin (grams per liter [g/L]), Hypo: All Grades	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Phosphate (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alanine Aminotransferase (U/L), Hyper: All Grades	7 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (U/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hypo: All Grades	6 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: All Grades	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Alkaline Phosphatase (units per liter [U/L]), Hyper: All Grades	6 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hyper: Grade 3/4	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Sodium (mmol/L), Hyper: Grade 3/4	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Potassium (mmol/L), Hypo: All Grades	4 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Glucose (mmol/L), Hypo: All Grades	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03	Creatinine (umol/L), Hyper: Grade 3/4	0 Participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades

Thyroid panel laboratory parameters/abnormalities: thyrotropin, free triiodothyronine (T3), free thyroxine (T4). Shift in thyroid panel severity from baseline grade low, normal, high and missing to the post baseline grades as low, normal, high and missing is reported in this outcome measure.

Time frame: Baseline, 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Normal (at post baseline)	2 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Normal (at post baseline)	4 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Normal (at post baseline)	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Low (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Low (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: High (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: High (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Normal (at post baseline)	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Normal (at post baseline)	6 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Normal (at post baseline)	5 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Low (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Low (at post baseline)	2 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Normal (at post baseline)	12 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to High (at post baseline)	2 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Low (at post baseline)	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to High (at post baseline)	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to High (at post baseline)	4 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to Low (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Normal (at post baseline)	14 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Normal (at post baseline)	12 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Low (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Low (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Missing (at post baseline)	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Normal (at post baseline)	12 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to High (at post baseline)	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Normal (at post baseline)	18 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Missing (at post baseline)	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Low (at post baseline)	4 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to High (at post baseline)	5 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Low (at post baseline)	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Normal (at post baseline)	12 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Low (at baseline) to Low (at post baseline)	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Missing (at post baseline)	3 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to High (at post baseline)	2 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Missing (at post baseline)	4 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Normal (at post baseline)	5 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to High (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to High (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to High (at post baseline)	5 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Low (at post baseline)	4 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to High (at post baseline)	1 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: High (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Triiodothyronine, Free: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyroxine, Free: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades	Thyrotropin: Normal (at baseline) to Missing (at post baseline)	0 Participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame: First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: Safety set included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	6 Participants
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	3 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	6 Participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	1 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	6 Participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	3 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	19 Participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	8 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	27 Participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	15 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	10 Participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	5 Participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)

OS was defined as the time from the start of treatment to the date of death due to any cause. If a death was not observed by the date of the analysis cut-off, OS was censored at the date of last contact. OS was estimated using the Kaplan-Meier method.

Time frame: From day of first dose till death due to any cause or date of last contact (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Value (MEDIAN)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)	14.7 months
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)	7.4 months
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)	6.5 months
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)	12.4 months
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)	2.2 months
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)	NA months

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)

irRR was defined as the percentage of participants who achieved immune-related best overall response (irBOR) of immune-related CR (irCR) or immune-related PR (irPR), as determined by the investigator per immune related response criteria (irRC). irBOR was the best response using irRC recorded from the start of study treatment until the end of treatment. irCR was the disappearance of all target lesions, irPR was a decrease in tumor burden by 50% or greater by a consecutive assessment at least 4 weeks after first documentation.

Time frame: From day of first dose till up to end of study treatment (for Phase 1b: maximum up to 33.7 months, for Phase 2: maximum up to 12.5 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Value (NUMBER)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)	16.7 percentage of participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)	16.7 percentage of participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)	0.0 percentage of participants
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)	0.0 percentage of participants
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)	3.7 percentage of participants
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)	0.0 percentage of participants

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382

The lower limit of quantitation (LLOQ) for analyte ARRY-382 was 5.00 nanogram per milliliter (ng/mL).

Time frame: Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hour(hr) (±5 min), 2 hours(hrs) (±10 min), 4 hrs (±20 min) and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2

Population: Pharmacokinetic (PK) set included all participants who had received any active study intervention (ARRY-382), with at least one post dose blood draw to determine plasma concentration of ARRY-382. Here Number Analyzed signifies number of participants evaluated for given time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	542 nanogram per milliliter	Geometric Coefficient of Variation 78.8
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	1170 nanogram per milliliter	Geometric Coefficient of Variation 76.5
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 4 Day 1 / Pre ARRY-382 dose	405 nanogram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	1200 nanogram per milliliter	Geometric Coefficient of Variation 57.6
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 5 Day 1 / Pre ARRY-382 dose	NA nanogram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	384 nanogram per milliliter	Geometric Coefficient of Variation 26.3
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	1530 nanogram per milliliter	Geometric Coefficient of Variation 45.2
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	283 nanogram per milliliter	Geometric Coefficient of Variation 422
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / Pre ARRY-382 dose	576 nanogram per milliliter	Geometric Coefficient of Variation 59.5
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 3 Day 1 / Pre ARRY-382 dose	565 nanogram per milliliter	Geometric Coefficient of Variation 39.5
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 15 / Pre ARRY-382 dose	616 nanogram per milliliter	Geometric Coefficient of Variation 43
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	1100 nanogram per milliliter	Geometric Coefficient of Variation 35.7
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	530 nanogram per milliliter	Geometric Coefficient of Variation 37.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	1310 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	1680 nanogram per milliliter	Geometric Coefficient of Variation 8.22
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 3 Day 1 / Pre ARRY-382 dose	305 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	497 nanogram per milliliter	Geometric Coefficient of Variation 201
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	2030 nanogram per milliliter	Geometric Coefficient of Variation 35.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	845 nanogram per milliliter	Geometric Coefficient of Variation 49
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	49.7 nanogram per milliliter	Geometric Coefficient of Variation 1130
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	566 nanogram per milliliter	Geometric Coefficient of Variation 28.8
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 15 / Pre ARRY-382 dose	533 nanogram per milliliter	Geometric Coefficient of Variation 34.2
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / Pre ARRY-382 dose	762 nanogram per milliliter	Geometric Coefficient of Variation 6.44
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	1600 nanogram per milliliter	Geometric Coefficient of Variation 106
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	2120 nanogram per milliliter	Geometric Coefficient of Variation 126
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	1440 nanogram per milliliter	Geometric Coefficient of Variation 142
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 15 / Pre ARRY-382 dose	888 nanogram per milliliter	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	305 nanogram per milliliter	Geometric Coefficient of Variation 263
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	2560 nanogram per milliliter	Geometric Coefficient of Variation 117
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	1430 nanogram per milliliter	Geometric Coefficient of Variation 195
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	827 nanogram per milliliter	Geometric Coefficient of Variation 64.2
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	757 nanogram per milliliter	Geometric Coefficient of Variation 46.8
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	1130 nanogram per milliliter	Geometric Coefficient of Variation 50
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / Pre ARRY-382 dose	1040 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 9 Day 1 / Pre ARRY-382 dose	350 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	664 nanogram per milliliter	Geometric Coefficient of Variation 194
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	1060 nanogram per milliliter	Geometric Coefficient of Variation 65.8
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	1010 nanogram per milliliter	Geometric Coefficient of Variation 44.7
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	683 nanogram per milliliter	Geometric Coefficient of Variation 43.7
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 15 / Pre ARRY-382 dose	862 nanogram per milliliter	Geometric Coefficient of Variation 57.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 3 Day 1 / Pre ARRY-382 dose	554 nanogram per milliliter	Geometric Coefficient of Variation 70.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 4 Day 1 / Pre ARRY-382 dose	1080 nanogram per milliliter	Geometric Coefficient of Variation 119
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 6 Day 1 / Pre ARRY-382 dose	798 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 10 Day 1 / Pre ARRY-382 dose	244 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / Pre ARRY-382 dose	330 nanogram per milliliter	Geometric Coefficient of Variation 2050
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	1320 nanogram per milliliter	Geometric Coefficient of Variation 97.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	1830 nanogram per milliliter	Geometric Coefficient of Variation 92.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	1630 nanogram per milliliter	Geometric Coefficient of Variation 66.6
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	1530 nanogram per milliliter	Geometric Coefficient of Variation 52.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 5 Day 1 / Pre ARRY-382 dose	92.6 nanogram per milliliter	Geometric Coefficient of Variation 13300
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 7 Day 1 / Pre ARRY-382 dose	573 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 8 Day 1 / Pre ARRY-382 dose	424 nanogram per milliliter	—
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	982 nanogram per milliliter	Geometric Coefficient of Variation 101
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 5 Day 1 / Pre ARRY-382 dose	1000 nanogram per milliliter	Geometric Coefficient of Variation 35.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	2900 nanogram per milliliter	Geometric Coefficient of Variation 4.73
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 3 Day 1 / Pre ARRY-382 dose	324 nanogram per milliliter	Geometric Coefficient of Variation 391
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	373 nanogram per milliliter	Geometric Coefficient of Variation 282
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 4 Day 1 / Pre ARRY-382 dose	728 nanogram per milliliter	Geometric Coefficient of Variation 85.2
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	2000 nanogram per milliliter	Geometric Coefficient of Variation 14.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	662 nanogram per milliliter	Geometric Coefficient of Variation 76.7
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	3000 nanogram per milliliter	Geometric Coefficient of Variation 9.01
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	2150 nanogram per milliliter	Geometric Coefficient of Variation 7.22
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 6 Day 1 / Pre ARRY-382 dose	1100 nanogram per milliliter	—
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / Pre ARRY-382 dose	1550 nanogram per milliliter	Geometric Coefficient of Variation 18.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	976 nanogram per milliliter	Geometric Coefficient of Variation 72.6
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 15 / Pre ARRY-382 dose	918 nanogram per milliliter	Geometric Coefficient of Variation 79.1
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	1220 nanogram per milliliter	Geometric Coefficient of Variation 64.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 15 / Pre ARRY-382 dose	485 nanogram per milliliter	Geometric Coefficient of Variation 117
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	500 nanogram per milliliter	Geometric Coefficient of Variation 52.6
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	695 nanogram per milliliter	Geometric Coefficient of Variation 145
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / Pre ARRY-382 dose	438 nanogram per milliliter	Geometric Coefficient of Variation 86.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	937 nanogram per milliliter	Geometric Coefficient of Variation 54.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 3 Day 1 / Pre ARRY-382 dose	336 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 7 Day 1 / Pre ARRY-382 dose	505 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	1580 nanogram per milliliter	Geometric Coefficient of Variation 79.6
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	1160 nanogram per milliliter	Geometric Coefficient of Variation 57.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 4 Day 1 / Pre ARRY-382 dose	522 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	1450 nanogram per milliliter	Geometric Coefficient of Variation 62.7
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 5 Day 1 / Pre ARRY-382 dose	76.6 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 6 Day 1 / Pre ARRY-382 dose	518 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	973 nanogram per milliliter	Geometric Coefficient of Variation 75.5

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099

Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00469099 was reported in this outcome measure. The LLOQ for analyte AR00469099 was 1.00 ng/mL.

Time frame: Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	74.9 nanogram per milliliter	Geometric Coefficient of Variation 85.3
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	133 nanogram per milliliter	Geometric Coefficient of Variation 72
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	10.6 nanogram per milliliter	Geometric Coefficient of Variation 750
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 5 Day 1 / Pre ARRY-382 dose	NA nanogram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	210 nanogram per milliliter	Geometric Coefficient of Variation 57.5
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 15 / Pre ARRY-382 dose	136 nanogram per milliliter	Geometric Coefficient of Variation 30.8
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	177 nanogram per milliliter	Geometric Coefficient of Variation 89.6
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 3 Day 1 / Pre ARRY-382 dose	121 nanogram per milliliter	Geometric Coefficient of Variation 81.8
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	36.3 nanogram per milliliter	Geometric Coefficient of Variation 219
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	166 nanogram per milliliter	Geometric Coefficient of Variation 66
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / Pre ARRY-382 dose	136 nanogram per milliliter	Geometric Coefficient of Variation 67.7
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	69.5 nanogram per milliliter	Geometric Coefficient of Variation 128
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 4 Day 1 / Pre ARRY-382 dose	79.9 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 15 / Pre ARRY-382 dose	73.7 nanogram per milliliter	Geometric Coefficient of Variation 62.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	96.4 nanogram per milliliter	Geometric Coefficient of Variation 62.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	83.6 nanogram per milliliter	Geometric Coefficient of Variation 69.2
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 3 Day 1 / Pre ARRY-382 dose	31.0 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / Pre ARRY-382 dose	199 nanogram per milliliter	Geometric Coefficient of Variation 82.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	NA nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	320 nanogram per milliliter	Geometric Coefficient of Variation 71.9
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	245 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	208 nanogram per milliliter	Geometric Coefficient of Variation 129
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	166 nanogram per milliliter	Geometric Coefficient of Variation 133
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	19.6 nanogram per milliliter	Geometric Coefficient of Variation 495
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	170 nanogram per milliliter	Geometric Coefficient of Variation 72.6
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / Pre ARRY-382 dose	188 nanogram per milliliter	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	177 nanogram per milliliter	Geometric Coefficient of Variation 94.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	8.57 nanogram per milliliter	Geometric Coefficient of Variation 404
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	57.2 nanogram per milliliter	Geometric Coefficient of Variation 151
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	205 nanogram per milliliter	Geometric Coefficient of Variation 88.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 15 / Pre ARRY-382 dose	190 nanogram per milliliter	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	241 nanogram per milliliter	Geometric Coefficient of Variation 73.8
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	305 nanogram per milliliter	Geometric Coefficient of Variation 62
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	313 nanogram per milliliter	Geometric Coefficient of Variation 77.8
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 5 Day 1 / Pre ARRY-382 dose	11.5 nanogram per milliliter	Geometric Coefficient of Variation 4020
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	119 nanogram per milliliter	Geometric Coefficient of Variation 49.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 15 / Pre ARRY-382 dose	210 nanogram per milliliter	Geometric Coefficient of Variation 78.8
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	254 nanogram per milliliter	Geometric Coefficient of Variation 29.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	21.0 nanogram per milliliter	Geometric Coefficient of Variation 234
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 8 Day 1 / Pre ARRY-382 dose	42.7 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	272 nanogram per milliliter	Geometric Coefficient of Variation 36.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	298 nanogram per milliliter	Geometric Coefficient of Variation 55.6
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 9 Day 1 / Pre ARRY-382 dose	30.6 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / Pre ARRY-382 dose	96.5 nanogram per milliliter	Geometric Coefficient of Variation 2860
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 10 Day 1 / Pre ARRY-382 dose	27.0 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	324 nanogram per milliliter	Geometric Coefficient of Variation 44.1
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 3 Day 1 / Pre ARRY-382 dose	123 nanogram per milliliter	Geometric Coefficient of Variation 210
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 4 Day 1 / Pre ARRY-382 dose	157 nanogram per milliliter	Geometric Coefficient of Variation 228
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 7 Day 1 / Pre ARRY-382 dose	61.5 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 6 Day 1 / Pre ARRY-382 dose	86.9 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	110 nanogram per milliliter	Geometric Coefficient of Variation 48.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	66.2 nanogram per milliliter	Geometric Coefficient of Variation 80.5
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	510 nanogram per milliliter	Geometric Coefficient of Variation 174
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	113 nanogram per milliliter	Geometric Coefficient of Variation 109
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 6 Day 1 / Pre ARRY-382 dose	141 nanogram per milliliter	—
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	561 nanogram per milliliter	Geometric Coefficient of Variation 152
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 3 Day 1 / Pre ARRY-382 dose	70.6 nanogram per milliliter	Geometric Coefficient of Variation 243
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	132 nanogram per milliliter	Geometric Coefficient of Variation 101
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	7.95 nanogram per milliliter	Geometric Coefficient of Variation 493
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 15 / Pre ARRY-382 dose	250 nanogram per milliliter	Geometric Coefficient of Variation 172
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / Pre ARRY-382 dose	511 nanogram per milliliter	Geometric Coefficient of Variation 189
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	475 nanogram per milliliter	Geometric Coefficient of Variation 173
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 4 Day 1 / Pre ARRY-382 dose	138 nanogram per milliliter	Geometric Coefficient of Variation 30
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	544 nanogram per milliliter	Geometric Coefficient of Variation 168
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	54.7 nanogram per milliliter	Geometric Coefficient of Variation 177
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 5 Day 1 / Pre ARRY-382 dose	170 nanogram per milliliter	Geometric Coefficient of Variation 10.4
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 4 Day 1 / Pre ARRY-382 dose	70.3 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 7 Day 1 / Pre ARRY-382 dose	103 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	157 nanogram per milliliter	Geometric Coefficient of Variation 50.7
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	102 nanogram per milliliter	Geometric Coefficient of Variation 68.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 5 Day 1 / Pre ARRY-382 dose	7.92 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	89.1 nanogram per milliliter	Geometric Coefficient of Variation 39.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	22.6 nanogram per milliliter	Geometric Coefficient of Variation 164
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	133 nanogram per milliliter	Geometric Coefficient of Variation 54.1
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	146 nanogram per milliliter	Geometric Coefficient of Variation 58.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 15 / Pre ARRY-382 dose	83.3 nanogram per milliliter	Geometric Coefficient of Variation 132
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	75.7 nanogram per milliliter	Geometric Coefficient of Variation 41.6
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 6 Day 1 / Pre ARRY-382 dose	110 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 2 Day 1 / Pre ARRY-382 dose	77.1 nanogram per milliliter	Geometric Coefficient of Variation 85.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 3 Day 1 / Pre ARRY-382 dose	54.0 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	60.8 nanogram per milliliter	Geometric Coefficient of Variation 52.9

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100

Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00469100 was reported in this outcome measure. The LLOQ for analyte AR00469100 was 1.00 ng/mL.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / Pre ARRY-382 dose	60.1 nanogram per milliliter	Geometric Coefficient of Variation 103
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 4 Day 1 / Pre ARRY-382 dose	31.1 nanogram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	41.7 nanogram per milliliter	Geometric Coefficient of Variation 79.2
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	47.1 nanogram per milliliter	Geometric Coefficient of Variation 109
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	19.5 nanogram per milliliter	Geometric Coefficient of Variation 667
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 5 Day 1 / Pre ARRY-382 dose	NA nanogram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	28.2 nanogram per milliliter	Geometric Coefficient of Variation 71.2
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 3 Day 1 / Pre ARRY-382 dose	63.2 nanogram per milliliter	Geometric Coefficient of Variation 108
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	104 nanogram per milliliter	Geometric Coefficient of Variation 75.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	108 nanogram per milliliter	Geometric Coefficient of Variation 108
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 15 / Pre ARRY-382 dose	70.7 nanogram per milliliter	Geometric Coefficient of Variation 81.2
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	138 nanogram per milliliter	Geometric Coefficient of Variation 81.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	105 nanogram per milliliter	Geometric Coefficient of Variation 98.3
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 3 Day 1 / Pre ARRY-382 dose	57.3 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / Pre ARRY-382 dose	107 nanogram per milliliter	Geometric Coefficient of Variation 45.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	169 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	228 nanogram per milliliter	Geometric Coefficient of Variation 39.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	210 nanogram per milliliter	Geometric Coefficient of Variation 27.1
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	NA nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	43.0 nanogram per milliliter	Geometric Coefficient of Variation 468
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	82.7 nanogram per milliliter	Geometric Coefficient of Variation 55.7
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	53.9 nanogram per milliliter	Geometric Coefficient of Variation 42.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 15 / Pre ARRY-382 dose	69.4 nanogram per milliliter	Geometric Coefficient of Variation 24.5
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	196 nanogram per milliliter	Geometric Coefficient of Variation 81.9
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	71.0 nanogram per milliliter	Geometric Coefficient of Variation 96.9
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	16.6 nanogram per milliliter	Geometric Coefficient of Variation 584
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	161 nanogram per milliliter	Geometric Coefficient of Variation 158
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	138 nanogram per milliliter	Geometric Coefficient of Variation 228
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / Pre ARRY-382 dose	146 nanogram per milliliter	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	268 nanogram per milliliter	Geometric Coefficient of Variation 141
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	67.7 nanogram per milliliter	Geometric Coefficient of Variation 40.5
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	110 nanogram per milliliter	Geometric Coefficient of Variation 40.5
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	219 nanogram per milliliter	Geometric Coefficient of Variation 131
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 15 / Pre ARRY-382 dose	116 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	116 nanogram per milliliter	Geometric Coefficient of Variation 75.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	165 nanogram per milliliter	Geometric Coefficient of Variation 81.7
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	139 nanogram per milliliter	Geometric Coefficient of Variation 57.4
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	65.4 nanogram per milliliter	Geometric Coefficient of Variation 64.8
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 3 Day 1 / Pre ARRY-382 dose	73.2 nanogram per milliliter	Geometric Coefficient of Variation 73.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 4 Day 1 / Pre ARRY-382 dose	108 nanogram per milliliter	Geometric Coefficient of Variation 109
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 5 Day 1 / Pre ARRY-382 dose	14.0 nanogram per milliliter	Geometric Coefficient of Variation 6560
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 7 Day 1 / Pre ARRY-382 dose	73.2 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 8 Day 1 / Pre ARRY-382 dose	51.3 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 9 Day 1 / Pre ARRY-382 dose	44.0 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 10 Day 1 / Pre ARRY-382 dose	33.8 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	61.0 nanogram per milliliter	Geometric Coefficient of Variation 337
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	114 nanogram per milliliter	Geometric Coefficient of Variation 69.1
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	102 nanogram per milliliter	Geometric Coefficient of Variation 62
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 6 Day 1 / Pre ARRY-382 dose	110 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	124 nanogram per milliliter	Geometric Coefficient of Variation 39.5
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / Pre ARRY-382 dose	35.2 nanogram per milliliter	Geometric Coefficient of Variation 977
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 15 / Pre ARRY-382 dose	106 nanogram per milliliter	Geometric Coefficient of Variation 94.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	218 nanogram per milliliter	Geometric Coefficient of Variation 74.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	85.5 nanogram per milliliter	Geometric Coefficient of Variation 84.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	265 nanogram per milliliter	Geometric Coefficient of Variation 65.5
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 4 Day 1 / Pre ARRY-382 dose	75.5 nanogram per milliliter	Geometric Coefficient of Variation 88.7
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	264 nanogram per milliliter	Geometric Coefficient of Variation 75.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	81.9 nanogram per milliliter	Geometric Coefficient of Variation 150
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 5 Day 1 / Pre ARRY-382 dose	112 nanogram per milliliter	Geometric Coefficient of Variation 46.2
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	56.4 nanogram per milliliter	Geometric Coefficient of Variation 83.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	21.3 nanogram per milliliter	Geometric Coefficient of Variation 553
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 3 Day 1 / Pre ARRY-382 dose	54.8 nanogram per milliliter	Geometric Coefficient of Variation 255
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / Pre ARRY-382 dose	184 nanogram per milliliter	Geometric Coefficient of Variation 91.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	191 nanogram per milliliter	Geometric Coefficient of Variation 92.5
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 6 Day 1 / Pre ARRY-382 dose	148 nanogram per milliliter	—
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 15 / Pre ARRY-382 dose	96.0 nanogram per milliliter	Geometric Coefficient of Variation 85.3
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 3 Day 1 / Pre ARRY-382 dose	32.7 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 7 Day 1 / Pre ARRY-382 dose	67.4 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	44.0 nanogram per milliliter	Geometric Coefficient of Variation 50.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	164 nanogram per milliliter	Geometric Coefficient of Variation 67.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 15 / Pre ARRY-382 dose	60.8 nanogram per milliliter	Geometric Coefficient of Variation 121
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 5 Day 1 / Pre ARRY-382 dose	11.7 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 6 Day 1 / Pre ARRY-382 dose	72.8 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	173 nanogram per milliliter	Geometric Coefficient of Variation 39.1
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	226 nanogram per milliliter	Geometric Coefficient of Variation 66.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	123 nanogram per milliliter	Geometric Coefficient of Variation 51.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	75.4 nanogram per milliliter	Geometric Coefficient of Variation 131
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 4 Day 1 / Pre ARRY-382 dose	67.6 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	107 nanogram per milliliter	Geometric Coefficient of Variation 77.8
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 2 Day 1 / Pre ARRY-382 dose	57.1 nanogram per milliliter	Geometric Coefficient of Variation 99.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	101 nanogram per milliliter	Geometric Coefficient of Variation 46.8

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870

Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00470870 was reported in this outcome measure. The LLOQ for analyte AR00470870 was 1.00 ng/mL.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / Pre ARRY-382 dose	99.1 nanogram per milliliter	Geometric Coefficient of Variation 80.8
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 4 Day 1 / Pre ARRY-382 dose	77.4 nanogram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	165 nanogram per milliliter	Geometric Coefficient of Variation 49.3
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	149 nanogram per milliliter	Geometric Coefficient of Variation 54.4
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	122 nanogram per milliliter	Geometric Coefficient of Variation 63.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	64.5 nanogram per milliliter	Geometric Coefficient of Variation 101
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	14.6 nanogram per milliliter	Geometric Coefficient of Variation 835
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	49.4 nanogram per milliliter	Geometric Coefficient of Variation 193
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	53.7 nanogram per milliliter	Geometric Coefficient of Variation 78.4
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	151 nanogram per milliliter	Geometric Coefficient of Variation 58.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 5 Day 1 / Pre ARRY-382 dose	NA nanogram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 15 / Pre ARRY-382 dose	105 nanogram per milliliter	Geometric Coefficient of Variation 86.9
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 3 Day 1 / Pre ARRY-382 dose	118 nanogram per milliliter	Geometric Coefficient of Variation 88.7
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / Pre ARRY-382 dose	294 nanogram per milliliter	Geometric Coefficient of Variation 49.3
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	36.7 nanogram per milliliter	Geometric Coefficient of Variation 2940
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	460 nanogram per milliliter	Geometric Coefficient of Variation 37.6
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	NA nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 3 Day 1 / Pre ARRY-382 dose	250 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	159 nanogram per milliliter	Geometric Coefficient of Variation 106
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	444 nanogram per milliliter	Geometric Coefficient of Variation 29
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	503 nanogram per milliliter	Geometric Coefficient of Variation 26.8
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 15 / Pre ARRY-382 dose	255 nanogram per milliliter	Geometric Coefficient of Variation 11
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	377 nanogram per milliliter	—
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	144 nanogram per milliliter	Geometric Coefficient of Variation 71.3
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	206 nanogram per milliliter	Geometric Coefficient of Variation 68.5
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	327 nanogram per milliliter	Geometric Coefficient of Variation 61.2
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	68.7 nanogram per milliliter	Geometric Coefficient of Variation 113
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	11.7 nanogram per milliliter	Geometric Coefficient of Variation 410
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	182 nanogram per milliliter	Geometric Coefficient of Variation 73.7
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	162 nanogram per milliliter	Geometric Coefficient of Variation 52.6
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 15 / Pre ARRY-382 dose	231 nanogram per milliliter	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / Pre ARRY-382 dose	216 nanogram per milliliter	—
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	283 nanogram per milliliter	Geometric Coefficient of Variation 68.8
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	306 nanogram per milliliter	Geometric Coefficient of Variation 47.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / Pre ARRY-382 dose	83.4 nanogram per milliliter	Geometric Coefficient of Variation 2600
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	46.9 nanogram per milliliter	Geometric Coefficient of Variation 403
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	140 nanogram per milliliter	Geometric Coefficient of Variation 97.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	150 nanogram per milliliter	Geometric Coefficient of Variation 56.8
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	244 nanogram per milliliter	Geometric Coefficient of Variation 58.1
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	337 nanogram per milliliter	Geometric Coefficient of Variation 70.2
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	320 nanogram per milliliter	Geometric Coefficient of Variation 65.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	337 nanogram per milliliter	Geometric Coefficient of Variation 55.3
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 3 Day 1 / Pre ARRY-382 dose	156 nanogram per milliliter	Geometric Coefficient of Variation 87
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 6 Day 1 / Pre ARRY-382 dose	73.5 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 8 Day 1 / Pre ARRY-382 dose	62.8 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 9 Day 1 / Pre ARRY-382 dose	73.8 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 10 Day 1 / Pre ARRY-382 dose	90.6 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 4 Day 1 / Pre ARRY-382 dose	161 nanogram per milliliter	Geometric Coefficient of Variation 113
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 5 Day 1 / Pre ARRY-382 dose	16.4 nanogram per milliliter	Geometric Coefficient of Variation 10600
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 7 Day 1 / Pre ARRY-382 dose	60.7 nanogram per milliliter	—
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	191 nanogram per milliliter	Geometric Coefficient of Variation 59.9
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 15 / Pre ARRY-382 dose	259 nanogram per milliliter	Geometric Coefficient of Variation 49.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	12.6 nanogram per milliliter	Geometric Coefficient of Variation 1100
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 15 / Pre ARRY-382 dose	307 nanogram per milliliter	Geometric Coefficient of Variation 74
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	348 nanogram per milliliter	Geometric Coefficient of Variation 40.3
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 5 Day 1 / Pre ARRY-382 dose	268 nanogram per milliliter	Geometric Coefficient of Variation 18.2
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	129 nanogram per milliliter	Geometric Coefficient of Variation 116
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	345 nanogram per milliliter	Geometric Coefficient of Variation 36.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	310 nanogram per milliliter	Geometric Coefficient of Variation 47.2
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / Pre ARRY-382 dose	285 nanogram per milliliter	Geometric Coefficient of Variation 58.4
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 4 Day 1 / Pre ARRY-382 dose	263 nanogram per milliliter	Geometric Coefficient of Variation 13.5
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	123 nanogram per milliliter	Geometric Coefficient of Variation 90.1
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 6 Day 1 / Pre ARRY-382 dose	419 nanogram per milliliter	—
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 3 Day 1 / Pre ARRY-382 dose	194 nanogram per milliliter	Geometric Coefficient of Variation 65
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	279 nanogram per milliliter	Geometric Coefficient of Variation 53.8
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	74.8 nanogram per milliliter	Geometric Coefficient of Variation 277
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 2 hrs Post ARRY-382 dose	189 nanogram per milliliter	Geometric Coefficient of Variation 59.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 8 hrs Post ARRY-382 dose	401 nanogram per milliliter	Geometric Coefficient of Variation 19.2
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 3 Day 1 / Pre ARRY-382 dose	194 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 4 Day 1 / Pre ARRY-382 dose	158 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 8 hrs Post ARRY-382 dose	148 nanogram per milliliter	Geometric Coefficient of Variation 46.7
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 6 Day 1 / Pre ARRY-382 dose	192 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 4 hrs Post ARRY-382 dose	486 nanogram per milliliter	Geometric Coefficient of Variation 18.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day1 / 4 hrs Post ARRY-382 dose	220 nanogram per milliliter	Geometric Coefficient of Variation 46.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 1 / 1 hr Post ARRY-382 dose	71.7 nanogram per milliliter	Geometric Coefficient of Variation 125
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 1 Day 15 / Pre ARRY-382 dose	242 nanogram per milliliter	Geometric Coefficient of Variation 33.5
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 2 hrs Post ARRY-382 dose	462 nanogram per milliliter	Geometric Coefficient of Variation 16.9
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / 1 hr Post ARRY-382 dose	316 nanogram per milliliter	Geometric Coefficient of Variation 26.4
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 5 Day 1 / Pre ARRY-382 dose	33.8 nanogram per milliliter	—
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 2 Day 1 / Pre ARRY-382 dose	224 nanogram per milliliter	Geometric Coefficient of Variation 34.1
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870	Cycle 7 Day 1 / Pre ARRY-382 dose	236 nanogram per milliliter	—

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)

PFS was defined as the time from the date of first dose of study drug to the earliest date of disease progression per RECIST v1.1, or death due to any cause, whichever occurs first. If a participant did not have a PFS event at the time of the analysis cut-off or at the start of any new anticancer therapy, PFS was censored at the date of last adequate tumor assessment. PD = at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of \>= 5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions.

Time frame: From day of first dose until disease progression or death due to any cause or till last tumor assessment date (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Value (MEDIAN)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)	4.7 months
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)	2.3 months
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)	1.4 months
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)	1.6 months
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)	1.4 months
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)	2.1 months

Secondary

Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Tmax was obtained from plasma concentration time curve. Tmax at single dose was reported at Cycle 1 Day 1 and Tmax at steady state was reported at Cycle 2 Day 1.

Time frame: Pre dose of ARRY-382 (120 minutes prior to administration), 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2

Population: PK set included all participants who had received any active study intervention (ARRY-382), with at least one post dose blood draw to determine plasma concentration of ARRY-382 and its metabolites (AR00469099, AR00469100 and AR00470870). Here Number Analyzed signifies number of participants evaluated for given time points.

Arm	Measure	Group	Value (MEDIAN)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	2.00 hours
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	2.00 hours
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	2.00 hours
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	3.00 hours
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	2.00 hours
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	7.94 hours
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	3.00 hours
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	7.98 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	4.03 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	7.68 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	4.01 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	4.18 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	2.98 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	7.81 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	4.18 hours
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	3.03 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	4.07 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	7.95 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	8.00 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	4.07 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	1.98 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	1.98 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	4.07 hours
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	8.00 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	7.50 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	4.03 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	2.00 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	4.00 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	1.97 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	1.98 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	5.88 hours
Phase 2: PD-1/PD-L1 Inhibitor-Refractory Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	2.00 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	5.83 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	3.90 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	5.90 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	2.00 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	5.78 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	4.07 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	2.00 hours
Phase 2: Pancreatic Ductal Adenocarcinoma (PDA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	3.03 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 ARRY-382	2.00 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469100	2.00 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469099	4.05 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00469099	4.17 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00470870	4.05 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 AR00469100	2.00 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 2 Day 1 ARRY-382	2.00 hours
Phase 2: Platinum-resistant Ovarian Cancer (prOVCA) Cohort	Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)	Cycle 1 Day 1 AR00470870	3.80 hours

Secondary

Phase 1b, Part A: Objective Response Rate (ORR)

ORR was defined as the percentage of participants who achieved a BOR of CR or PR as determined by investigator review of radiographic disease assessments per RECIST v1.1. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD. The analysis was based on confirmed responses for which CR or PR must be confirmed by repeat disease assessment studies performed no less than 4 weeks after the criteria for response were first met to qualify as CR or PR, respectively.

Time frame: From day of first dose to 30 days after last dose (maximum up to 34.7 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab.

Arm	Measure	Value (NUMBER)
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: Objective Response Rate (ORR)	16.7 percentage of participants
Phase 1b, Part A: 300 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: Objective Response Rate (ORR)	16.7 percentage of participants
Phase 1b, Part A: 400 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 1b, Part A: Objective Response Rate (ORR)	0.0 percentage of participants

Secondary

Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation

Tumor markers were measured for tumor type from serum samples obtained from participants in Phase 2. Mean change from baseline was reported in this outcome measure.

Time frame: Baseline, Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment discontinuation (before 13.5 months)

Population: FAS included all participants who received at least 1 dose (partial or full) of ARRY-382 or pembrolizumab. This outcome measure was planned in prOVCA cohort. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (MEAN)	Dispersion
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 1 Day 1	578.6 microgram per milliliter	Standard Deviation 626.3302643
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 1 Day 8	803.3181818 microgram per milliliter	Standard Deviation 808.9155788
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 1 Day 15	1279.833333 microgram per milliliter	Standard Deviation 1298.144638
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 2 Day 1	1485.6 microgram per milliliter	Standard Deviation 1368.310653
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 3 Day 1	1558.4 microgram per milliliter	Standard Deviation 1502.22728
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 4 Day 1	1980 microgram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 5 Day 1	778 microgram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 6 Day 1	1730 microgram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Cycle 7 Day 1	2080 microgram per milliliter	—
Phase 1b, Part A: 200 mg ARRY-382 + 2 mg/kg Pembrolizumab	Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation	Treatment discontinuation	1743.833333 microgram per milliliter	Standard Deviation 1817.18193

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)

Phase 2 Cohorts: Objective Response Rate (ORR)

Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Phase 1b, Part A and Phase 2 Cohorts: Duration of Response (DOR)

Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)

Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades

Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)

Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100

Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870

Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)

Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)

Phase 1b, Part A: Objective Response Rate (ORR)

Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation